Alpha Teknova (TKNO) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue increased 17% year-over-year to $9.6 million, driven by strong Clinical Solutions growth, while Lab Essentials was flat or slightly down.

• Net loss for Q3 2024 was $7.6 million ($0.15 per share), improved from $10.2 million ($0.34 per share) in Q3 2023, reflecting lower operating expenses and cost controls.

• Free cash outflow was $2.4 million, the lowest in over three years, and liquidity was strengthened by a $15.1–$15.4 million capital raise.

• Infrastructure and liquidity are in place to support scaling up to $200 million in revenue and reaching profitability without additional capital.

• Continued expense reductions, capital management, and operational improvements contributed to improved results.

Financial highlights

• Q3 2024 total revenue was $9.6 million, up 17% from $8.2 million in Q3 2023.

• Gross profit was $0.1 million (gross margin 0.9%), down from $1.5 million (18.0%) in Q3 2023, impacted by a $2.8 million non-recurring inventory write-down; excluding this, gross margin was 29.8%.

• Adjusted EBITDA was negative $5.0 million, or negative $2.2 million excluding the inventory charge.

• Operating expenses were $7.5 million, down from $10.2 million in Q3 2023, reflecting reduced headcount and spending.

• Cash and equivalents were $31.7 million, with $12.1 million in gross debt as of September 30, 2024.

Outlook and guidance

• 2024 total revenue guidance reiterated at $35–$38 million, implying flat year-over-year performance, with Lab Essentials expected to grow approximately 2%.

• Free cash outflow for 2024 now expected to be less than $16 million, improved from prior $18 million estimate.

• Adjusted EBITDA break-even projected at $50–$55 million annualized revenue.

• Management expects double-digit revenue growth in the second half of 2024 and aims to build momentum into 2025.

• No longer substantial doubt about ability to continue as a going concern for the next twelve months, following cost reductions, capital raise, and credit agreement amendment.